# PAREXEL International Corporation

PAREXEL International Corporation is an Asset Manager based in Durham, United States.

## Overview

- **Organization type:** Asset Manager
- **Headquarters:** Durham, United States
- **Region:** North America
- **Address:** Durham, NC, United States
- **Assets under management:** Undisclosed
- **Website:** www.parexel.com
- **LinkedIn:** https://www.linkedin.com/company/parexel

## Regulatory record

- **Reports private funds:** No

## About

For over 35 years Parexel has been a trusted global CRO and biopharmaceutical services company. Learn more about how we can help.

## Sectors

- Healthcare Services
- Clinical Research
- Biopharmaceutical Services

## People

- Chris Learn — Vice President, Cell and Gene Therapy, Center of Excellence
- Steve Winitsky — Senior Vice President
- Stefan Zietze — Executive Director
- Hicham El Bariqi — Director, Cell & Gene Therapy
- Jingke Yang — Senior Medical Director

## Questions

### Who runs investment decisions at PAREXEL International?

PAREXEL is a clinical research organization rather than an investment firm. The leadership team is composed of executives such as Senior Vice President Steve Winitsky and Vice President Chris Learn, who oversee the firm's cell and gene therapy and other therapeutic areas (per the firm's website). Strategic and operational decisions are made by the executive leadership, whose full roster is listed on the firm's about page.

### How does PAREXEL source proprietary deal flow?

As a contract research organization, PAREXEL does not follow a traditional investment deal flow model. The firm generates revenue by providing clinical development services to biopharmaceutical clients, including Phase I-IV trials, regulatory strategy, and market access planning. Client relationships are built through its therapeutic expertise and global operational reach.

### Does PAREXEL participate in fund commitments or only direct deals?

PAREXEL does not participate in fund commitments or direct investments. The firm's business model is based on providing clinical research services, including clinical trials, regulatory consulting, and market access support, to pharmaceutical and biotechnology companies. Its revenue comes from service contracts, not from capital allocation.

### What investment stages does PAREXEL typically target?

PAREXEL specializes in clinical development services spanning Phase I through Phase IV trials. This covers early-stage investigational drug studies through post-market surveillance. The firm also offers portfolio management and asset valuation, early development and innovation, and approval and access support.

### Which sectors does PAREXEL explicitly avoid?

The firm does not publicly disclose excluded sectors. Its stated therapeutic areas include neuroscience, general medicine, infectious disease and vaccines, immunology, oncology, hematology, ophthalmology, cell and gene therapies, pediatrics, and rare diseases. No explicit avoided sectors are listed.

## Related profiles

- [E Ink Corp.](https://altss.com/profile/e-ink-corp)
- [eGames LLC](https://altss.com/profile/egames-llc)

---

Last updated: 2026-06-03T20:00:00.000Z

Canonical page: https://altss.com/profile/parexel-international-corporation

Maintained by Altss — https://altss.com — methodology: https://altss.com/methodology